Verified email-pattern data for Fosun Kairos | 复星凯瑞 is currently limited. You can still use the company insights and contact sections below.
Being founded in 2017 and a division of Fosun Pharma, Shanghai Fosun Kairos Biotechnology Co., Ltd. is a high-tech biopharmaceutical enterprise. Fosun Kairos, since its establishment, has committed to the R&D, industrialization and commercialization of cell therapies against tumors, with the mission of "Cure the Incurable, Enlighten the Life" and its vision to be a most valuable leading one in the field of cell and gene therapy.
Fosun Kairos has introduced Yescarta®, a CAR-T therapy for treating relapsed or refractory non-Hodgkin lymphoma, from U.S. Kite Pharma and localized its production in China. In June 2021, Fosun Kairos received approval to launch China's first CAR-T therapy, YIKAIDA (Axicabtagene Ciloleucel Injection, a local version of Yescarta®). In June 2023, YIKAIDA was approved for another indication, i.e., the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. The launch of YIKAIDA marked the inaugural year of CAR-T therapy in China and continues to drive high-quality progress in lymphoma treatment.
Fosun Kairos has established a cell-therapy R&D center and a technology platform covering over 2000 square meters in Zhangjiang, Shanghai. Assembling a team of skilled scientists with high academic qualification from both domestic and abroad, the Company is dedicated to the early-stage research and development as well as evidence-based clinical projects of CAR-T, through technology license-in, independent innovation and cooperative development, aiming to build a sustainable innovation pipeline in cell therapy.
Looking forward, Fosun Kairos will function as the core platform for Fosun Pharma's cell therapy technologies, concentrating on tumor immunotherapy with a goal to reach the global market. It aims to become a worldwide leader in cell therapy, offering more hope for cures to patients globally.
Company Details
- Employees
- 76
- Founded
- -
- Address
- No.777 Shengrong Road, 3f,office Building,china
- Industry
- Biotechnology Research
- Website
- https://www.fosunkairos.com/
- Keywords
- Cell Therapy, Immunotherapy, CAR-T.
- HQ
- Shanghai, Shanghai
Fosun Kairos | 复星凯瑞 Questions
Fosun Kairos | 复星凯瑞's website is https://www.fosunkairos.com/
Fosun Kairos | 复星凯瑞's LinkedIn profile is https://cn.linkedin.com/company/fosunkairos
Fosun Kairos | 复星凯瑞 has
76 employees.
View email and phone details for 76
employees at Fosun Kairos | 复星凯瑞.
Fosun Kairos | 复星凯瑞's industry is
Biotechnology Research
Fosun Kairos | 复星凯瑞's top competitors are
Overland Pharmaceuticals,
Kite Pharma,
Novartis,
Iaso Biotherapeutics（驯鹿生物）,
Jw Therapeutics 药明巨诺,
Hengrui Pharma,
Fosun Pharma,
Carsgen Therapeutics,
Beigene,
Astrazeneca.
Fosun Kairos | 复星凯瑞's categories are Biotechnology Research
Fosun Kairos | 复星凯瑞's founding year is 2017
Explore related pages
Related company profiles:
Top Fosun Kairos | 复星凯瑞 Employees
-
-
-
Maria Wu
吴靖娴
Jing'an District, Shanghai, China, China1eddingpharm.com -
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.